Successful long-time treatment with mycophenolate-mofetil in a child with acquired factor VIII inhibitor

2012 ◽  
Vol 32 (S 01) ◽  
pp. S75-S78 ◽  
Author(s):  
C. Niekrens ◽  
K.-W. Sykora ◽  
C. Wermes
Keyword(s):  
Factor Viii ◽  
Half Life ◽  
High Titer ◽  
Term Treatment ◽  
High Dose ◽  
Severe Bleeding ◽  
Factor Viii Inhibitor ◽  
Long Term Treatment ◽  
Viii Inhibitor ◽  
Acquired Factor Viii Inhibitor

SummaryHere, we report about a boy (age: 18 years) who developed an acquired factor VIII inhibitor at the age of 9 years. He presented with bleeding in his right ankle, multiple haematomas and a high-titer factor VIII type II inhibitor (400 BU). Therapy: He received treatment with MMF (CellCept→), dexamethasoneimmunoglobulin pulses, and rituximab together with high dose FVIII (Hannover protocol). His inhibitor titer decreased rapidly, and half-life and recovery normalized. Inhibitor titres increased after reduction of the factor VIII dose, and increased further after MMF was stopped. A second treatment course with MMF again resulted in reduction of the titre, improvement in half life and recovery, and no more bleedings. Inhibitor reappeared with MMF dose reduction, again accompanied by severe bleeding. Additional rituximab stopped the bleedings, and treatment with MMF has been continued since. Conclusion: Although the laboratory parameters showed no complete remission, severe bleedings and expensive factor replacement could be avoided by long-term treatment with MMF.

Role of Plasmapheresis In Management of Acquired Factor VIII Inhibitor

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4656-4656
Author(s):  
Ratesh Khillan ◽  
Rabia Latif ◽  
Gurinder Sidhu ◽  
Elizabeth Gloster ◽  
Albert S. Braverman ◽  
...  
Keyword(s):  
Factor Viii ◽  
Ct Scan ◽  
Case Reports ◽  
High Dose ◽  
Factor Viii Inhibitor ◽  
Inhibitor Level ◽  
Viii Inhibitor ◽  
Acquired Factor Viii Inhibitor ◽  
Dose Factor

Abstract Abstract 4656 A 91-year-old woman with past medical history of hypertension presented with hematuria. There were no ecchymosis, Petechiae or other obvious active bleeding. Her hemoglobin was 11.4 g/dl on presentation hematuria got worse and her hemoglobin drops to 7.6 g/dl over next 48 hours and she was hemodynamically unstable. She was transferred to the Medical Intensive Care Unit for resuscitation with IV fluids and PRBCs. Coagulation tests revealed a prolongation of activated partial thromboplastin time of more than 100 seconds (control 33 seconds) which could not be corrected with mixing normal plasma. Diagnosis of acquired factor VIII inhibitor was considered and recombinant activated factor VII (rFVIIa) was initiated. The factor VIII activity level was reduced to less than 1%. Bethesda assay demonstrated the presence of a factor VIII inhibitor at 103.8 Bethesda units per ml (BU/ml), other coagulation studies were with in normal range. CT scan of her abdomen showed retroperitoneal hematoma. rFVIIa was started at 50 units/kg body weight every 3 hours and subsequently increased to 200 units/kg. She was simultaneously started on steroids. Her hematuria did not improve in spite of high dose rFVIIa. On day 4 rFVIIa was tapered and switched to 50 units/kg FEIBA (Factor eight inhibitor bypass agent). She also received Rituximab 375 mg/m2. We continued FEIBA until day 7 but her hematuria did not improve, she required more than 10 units of Packed Red Blood Cells PRBCs during this period. On day 7 we decided to start plasmapheresis as there were some case reports of using plasmapheresis with or without immunoadsorption columns (which are currently not available in US). We started plasmapheresis and gave her 2 doses of IVIG (Immunoglobulin). Her pre and post plasmapheresis inhibitor levels were 104 BU/ml and 54 BU/ml respectively. Her urine turned pink and her Prbc demand decreased. A second plasmapheresis was done 2 days later showed significant decrease of inhibitor level from 80 BU/ml to 14.5 BU/ml. Her hematuria resolved by next day. We continued her on FEIBA for three more days she did not have hematuria and she did not require any PRBCs. CT scan of abdomen showed decrease in size of retroperitoneal hematoma. Cyclophosphamide 1000 mg was given for induction of immune tolerance followed by high dose factor VIII (100 IU/KG) as per Bonn protocol. Her factor VIII levels and factor VIII inhibitor levels were checked every day before and after Factor VIII infusion. Her inhibitor level is ranging between 14–16 BU/ml she is not bleeding any more and her abdominal hematoma is resolved. Her pre and post transfusion factor VIII levels ranges between 30–40% and 120–140%. respectively. Patient is still getting factor VIII everyday. Role of plasmapheresis is not very well defined in acquired Factor VIII inhibitor patients. Acquired hemophilia is a rare autoimmune disorder in which the patient develop an autoantibody directed against coagulation factor VIII leading to a clinically bleeding diathesis. There are few case reports in literature showing efficacy of Plasmapheresis in this disorder. This is a rare condition and it is very difficult to find large randomized trial to establish a standard of care. Patient mentioned above did not respond to rFVIIa or FEIBA. In our observation plasmapheresis with IVIG proved to be an effective method of rapidly reducing the inhibitor level. In case of life threatening bleeding we need to reduce the inhibitor level quickly. We also observed that once inhibitor level was low bleeding stopped. Immune induction therapy with cyclophosphamide followed by high dose factor VIII was successful in maintaining low inhibitor level. Disclosures: Kessler: Grifols S.A.: Research Funding.

An Acquired Factor VIII Inhibitor Responsive to High-Dose Gamma Globulin

1987 ◽  
Vol 58 (04) ◽  
pp. 1005-1007 ◽  
Author(s):  
David Green ◽  
Hau C Kwaan
Keyword(s):  
Factor Viii ◽  
Gamma Globulin ◽  
Clotting Factor ◽  
Uneventful Recovery ◽  
High Dose ◽  
Factor Viii Inhibitor ◽  
Minimal Trauma ◽  
Viii Inhibitor ◽  
Acquired Factor Viii Inhibitor ◽  
Clotting Factor Concentrates

SummaryA 55-year-old previously well woman noted easy bruising and developed a swollen, painful leg after minimal trauma. A compartment syndrome was diagnosed, and medial and lateral fasciotomies were performed with evacuation of a massive hematoma. However, blood rapidly reaccumulated in the wound. The VILI : C level was 2%, and 4 Bethesda units of factor VIII inhibitor were detected. After initial treatment with clotting factor concentrates and corticosteroids failed to control bleeding or reduce inhibitor titers, gamma globulin, 25 g daily for 5 days, was administered. The inhibitor became undetectable, VIII :C levels rose, and bleeding stopped. However, 5 days later VIII :C levels were again low and bleeding recurred. A second course of gamma globulin, 50 g daily for 2 days, was accompanied by a prompt increase in VIII :C, and uneventful recovery. In conclusion, in this patient with an autoantibody to Vili : C, a response to gamma globulin was observed on two occasions, and the second response came when steroids were being tapered and the patient was on no other medication.

Low response to high‐dose intravenous immunoglobulin in the treatment of acquired factor VIII inhibitor

1996 ◽  
Vol 95 (4) ◽  
pp. 750-753 ◽  
Author(s):  
Laurent Crenier ◽  
Jean Ducobu ◽  
Jean‐Marin Des Grottes ◽  
Jean Cerny ◽  
Christian Delaunoit ◽  
...  
Keyword(s):  
Factor Viii ◽  
Intravenous Immunoglobulin ◽  
High Dose ◽  
Factor Viii Inhibitor ◽  
Viii Inhibitor ◽  
Acquired Factor Viii Inhibitor

scholarly journals A Case of an Acquired Factor VIII Inhibitor Complicated by Multiple Treatment-Related Opportunistic Infections and Review of the Literature

2013 ◽  
Vol 2013 ◽  
pp. 1-4
Author(s):  
Anna L. Hutchinson ◽  
Yi Ling Tan ◽  
Giselle Kidson-Gerber
Keyword(s):  
Factor Viii ◽  
Opportunistic Infections ◽  
Invasive Pulmonary Aspergillosis ◽  
Severe Bleeding ◽  
Factor Viii Inhibitor ◽  
Pneumocystis Jiroveci ◽  
Multiple Treatment ◽  
Threatening Condition ◽  
Viii Inhibitor ◽  
Acquired Factor Viii Inhibitor

This case report describes a patient with an idiopathic acquired Factor VIII inhibitor and severe bleeding. She was treated with rituximab after failing first-line treatment with steroids and cyclophosphamide. Two months following rituximab treatment, our patient developed a succession of severe opportunistic infections requiring intensive care unit admission. Over a period of 12 weeks she required treatment forPseudomonas aeruginosasepticaemia, herpes simplex gingivostomatitis and pharyngotonsillitis, clostridium difficile-related diarrhoea, systemic cytomegalovirus infection, pneumocystis jiroveci, and invasive pulmonary aspergillosis lung infections. After significant rehabilitation, the patient was finally discharged following a 5-month admission. This case highlights the complexity of balancing a life-threatening condition with the side effects of treatment. It also raises the issue of routine prophylaxis for immunosuppression in nonmalignant conditions, which will become a common dilemma with the expanding indications for rituximab use.

scholarly journals A Case with Severe Bleeding Caused by the Acquired Factor VIII Inhibitor.

2000 ◽  
Vol 11 (8) ◽  
pp. 401-405
Author(s):  
Takayuki Karino ◽  
Hanae Nakashima ◽  
Yasuhiro Fujinaga ◽  
Jun Tanabe ◽  
Niro Okimoto
Keyword(s):  
Factor Viii ◽  
Severe Bleeding ◽  
Factor Viii Inhibitor ◽  
Viii Inhibitor ◽  
Acquired Factor Viii Inhibitor

scholarly journals An Acquired Factor VIII Inhibitor in a Patient with HIV and HCV: A Case Presentation and Literature Review

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
S. B. Zeichner ◽  
A. Harris ◽  
G. Turner ◽  
M. Francavilla ◽  
J. Lutzky
Keyword(s):  
Factor Viii ◽  
High Titer ◽  
Laboratory Research ◽  
Factor Viii Inhibitor ◽  
Case Presentation ◽  
Fviii Inhibitor ◽  
First Case ◽  
History Of ◽  
Viii Inhibitor ◽  
Acquired Factor Viii Inhibitor

Introduction. Despite its low incidence, acquired factor VIII inhibitor is the most common autoantibody affecting the clotting cascade. The exact mechanism of acquisition remains unclear, but postpartum patients, those with autoimmune conditions or malignancies, and those with exposure to particular drugs appear most susceptible. There have been several case reports describing acquired FVIII inhibitors in patients receiving interferon alpha for HCV treatment and in patients being treated for HIV. To our knowledge, this is the first case of a patient with HCV and HIV who was not actively receiving treatment for either condition.Case Presentation. A 57-year-old Caucasian male with a history of HIV and HCV was admitted to our hospital for a several day history of progressively worsening right thigh bruising and generalized weakness. CTA of the abdominal arteries revealed large bilateral retroperitoneal hematomas. Laboratory studies revealed the presence of a high titer FVIII inhibitor.Conclusion. Our case of a very rare condition highlights the importance of recognizing and understanding the diagnosis of acquired FVIII inhibitor. Laboratory research and clinical data on the role of newer agents are needed in order to better characterize disease pathogenesis, disease associations, genetic markers, and optimal disease management.

Sign in / Sign up

Export Citation Format

Share Document